Ascletis Pharma scraps liver disease program; Another reverse merger

Plus, news about Benev­o­len­tAI, Adap­tive Biotech­nolo­gies, Ei­sai, CNX Ther­a­peu­tics, Van­da Phar­ma­ceu­ti­cals and Nu­cle­ai:

As­cle­tis Phar­ma ends liv­er dis­ease pro­gram: The Chi­nese biotech will not pur­sue fur­ther de­vel­op­ment of ASC42 for pri­ma­ry bil­iary cholan­gi­tis af­ter Phase 2 da­ta sug­gest­ed a lack of com­pet­i­tive­ness ver­sus com­pet­ing can­di­dates. As­cle­tis al­so dropped clin­i­cal work on the FXR ag­o­nist in he­pati­tis B. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.